Key Details
Price
$39.22Annual Revenue
$5.45 MAnnual EPS
-$5.15Annual ROE
-54.90%Beta
1.12Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting.
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today.
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET.
– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment –
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN –
FAQ
- What is the primary business of SpringWorks Therapeutics?
- What is the ticker symbol for SpringWorks Therapeutics?
- Does SpringWorks Therapeutics pay dividends?
- What sector is SpringWorks Therapeutics in?
- What industry is SpringWorks Therapeutics in?
- What country is SpringWorks Therapeutics based in?
- When did SpringWorks Therapeutics go public?
- Is SpringWorks Therapeutics in the S&P 500?
- Is SpringWorks Therapeutics in the NASDAQ 100?
- Is SpringWorks Therapeutics in the Dow Jones?
- When was SpringWorks Therapeutics's last earnings report?
- When does SpringWorks Therapeutics report earnings?
- Should I buy SpringWorks Therapeutics stock now?